Sleep Cycle reports early interest ahead of launch
By HME News Staff
Updated 12:21 PM CDT, Wed April 8, 2026
GOTHENBURG, Sweden – More than 150,000 people have registered interest in an upcoming sleep apnea risk detection solution from Sleep Cycle ahead of its commercial launch. The AI-powered sleep tech company says strong early demand underscores a significant need within sleep health and supports is strategic expansion into medical technology and scalable digital health solutions. “Sleep apnea remains significantly underdiagnosed, despite its serious impact on long-term health and quality of life,” said Erik Jivmark, CEO of Sleep Cycle. “Seeing more than 150,000 individuals register their interest ahead of commercial availability reinforces our conviction that there is clear demand for more accessible solutions for early detection of sleep apnea risk.” The interest group consists primarily of users in the United States and the United Kingdom, with a balanced gender distribution and a clear overrepresentation of adults aged 45 and above – a demographic disproportionately affected by undiagnosed sleep apnea, Sleep Cycle says. Globally, the condition is estimated to impact nearly 1 billion people, with the majority remaining undiagnosed.
Comments